- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
- Drug
- Lead sponsor
- AsclepiX Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Los Angeles, California • St. Petersburg, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose
- Drug
- Lead sponsor
- AsclepiX Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Springfield, Massachusetts • St Louis, Missouri • Asheville, North Carolina + 1 more
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
- Drug
- Lead sponsor
- AsclepiX Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Los Angeles, California • St. Petersburg, Florida + 7 more